English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Fifteen patients with clinical diagnosis of dilated cardiomyopathy (DCMP) were followed for 3 to 34 months. Serum neopterin and β 2 -microglobulin concentrations were measured by radioimmunoassay. According to the changes of neopterin and β 2 microglobulin levels in the follow-up study patients were divided into three groups. The course of disease in group 1 (5 patients with constant normal neopterin level &lt;9 nmol/L) during the study) was stable without deterioration and increase of New York Heart Association (NYHA) Class. In group 2 (2 patients with raised neopterin in levels at the beginning of the study) some clinical improvement was associated with normalization of neopterin concentration. In group 3 (8 patients) the relation between the disease progression and increasing neopterin level was observed. The data of this study clearly indicated that neopterin measurements had a predictive value in patients with clinical diagnosis of DCMP.

Serum Neopterin - Possible Marker to Predict Progression of Dilated Cardiomyopathy